These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells. Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR Cancer Treat Rep; 1985; 69(7-8):851-7. PubMed ID: 4016794 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. Rustum YM; Riva C; Preisler HD Semin Oncol; 1987 Jun; 14(2 Suppl 1):141-8. PubMed ID: 3589689 [No Abstract] [Full Text] [Related]
7. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Abe I; Saito S; Hori K; Suzuki M; Sato H Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175 [TBL] [Abstract][Full Text] [Related]
8. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322 [TBL] [Abstract][Full Text] [Related]
9. Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells. Ross DD; Joneckis CC; Song TH; Wu RK Cancer Res; 1988 Feb; 48(3):517-21. PubMed ID: 3335018 [TBL] [Abstract][Full Text] [Related]
10. Ara-CTP metabolism following hydroxyurea or methotrexate treatment in human leukemia cell lines. Kubota M; Takimoto T; Kitoh T; Tanizawa A; Akiyama Y; Kiriyama Y; Mikawa H Adv Exp Med Biol; 1989; 253B():363-7. PubMed ID: 2610124 [No Abstract] [Full Text] [Related]
11. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. Riva CM; Rustum YM Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596 [TBL] [Abstract][Full Text] [Related]
12. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Gandhi V; Estey E; Du M; Keating MJ; Plunkett W Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841 [TBL] [Abstract][Full Text] [Related]
13. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity. Tanaka M; Yoshida S Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933 [TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573 [TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Estey EH; Plunkett W; Kantarjian H; Rios MB; Keating MJ Leuk Lymphoma; 1993; 10 Suppl():115-21. PubMed ID: 8481661 [No Abstract] [Full Text] [Related]
16. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. Plunkett W; Iacoboni S; Keating MJ Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439 [No Abstract] [Full Text] [Related]
17. Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line. Tanizawa A; Kubota M; Takimoto T; Kito T; Akiyama Y; Kiriyama Y; Mikawa H Adv Exp Med Biol; 1989; 253B():349-54. PubMed ID: 2610122 [No Abstract] [Full Text] [Related]
18. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine. Grant S; Turner A; Nelms P; Yanovich S Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843 [TBL] [Abstract][Full Text] [Related]
19. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697 [No Abstract] [Full Text] [Related]
20. Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine. Howell SB; Streifel JA; Pfeifle CE Med Pediatr Oncol; 1982; 10 Suppl 1():81-91. PubMed ID: 6761570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]